Novartis AG ADR (NVS)vsDentsply Sirona Inc (XRAY)
NVS
Novartis AG ADR
$148.38
-0.99%
HEALTHCARE · Cap: $273.77B
XRAY
Dentsply Sirona Inc
$10.00
+1.21%
HEALTHCARE · Cap: $2.02B
Smart Verdict
WallStSmart Research — data-driven comparison
Novartis AG ADR generates 1437% more annual revenue ($56.58B vs $3.68B). NVS leads profitability with a 23.9% profit margin vs -17.1%. XRAY appears more attractively valued with a PEG of 0.72. XRAY earns a higher WallStSmart Score of 54/100 (C-).
NVS
Hold49
out of 100
Grade: D+
XRAY
Buy54
out of 100
Grade: C-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-62.1%
Fair Value
$91.39
Current Price
$148.38
$56.99 premium
Margin of Safety
+70.6%
Fair Value
$46.69
Current Price
$10.00
$36.69 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 35 in profit
Strong operational efficiency at 30.5%
Keeps 24 of every $100 in revenue as profit
Generating 2.9B in free cash flow
Reasonable price relative to book value
Growing faster than its price suggests
Areas to Watch
Grey zone — moderate risk
Elevated debt levels
Expensive relative to growth rate
Revenue declined 0.7%
0.1% revenue growth
Operating margin of 3.4%
Elevated debt levels
ROE of -37.7% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : NVS
The strongest argument for NVS centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 23.9% and operating margin at 30.5%.
Bull Case : XRAY
The strongest argument for XRAY centers on Price/Book, PEG Ratio. PEG of 0.72 suggests the stock is reasonably priced for its growth.
Bear Case : NVS
The primary concerns for NVS are Altman Z-Score, Debt/Equity, PEG Ratio.
Bear Case : XRAY
The primary concerns for XRAY are Revenue Growth, Operating Margin, Debt/Equity. Debt-to-equity of 1.77 is elevated, increasing financial risk.
Key Dynamics to Monitor
NVS profiles as a declining stock while XRAY is a turnaround play — different risk/reward profiles.
XRAY carries more volatility with a beta of 0.91 — expect wider price swings.
XRAY is growing revenue faster at 0.1% — sustainability is the question.
NVS generates stronger free cash flow (2.9B), providing more financial flexibility.
Bottom Line
XRAY scores higher overall (54/100 vs 49/100). Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Novartis AG ADR
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Novartis AG researches, develops, manufactures and markets medical devices worldwide. The company is headquartered in Basel, Switzerland.
Visit Website →Dentsply Sirona Inc
HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA
Dentsply Sirona is an American dental equipment manufacturer and dental consumables producer that markets its products in over 120 countries.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?